Last updated: 11/07/2018 18:36:59
A Multicentre, Randomised, Double-Blind Comparison of Alosetron 1mg bd against Trimebutine 200mg tds for 12 weeks in the Treatment of Female Patients with Irritable Bowel Syndrome.
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Multicentre, Randomised, Double-Blind Comparison of Alosetron 1mg bd against Trimebutine 200mg tds for 12 weeks in the Treatment of Female Patients with Irritable Bowel Syndrome.
Trial description: A Multicentre, Randomised, Double-Blind Comparison of Alosetron 1mg bd against Trimebutine 200mg tds for 12 weeks in the Treatment of Female Patients with Irritable Bowel Syndrome.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Efficacy of alosetron in the treatment of women with diarrhoea-predominant ibs. Gerald Holtmannl, Roger Jones Luis Rodrigo Saez Raihana Ehsanullah Philippa Crompton Loretta Jacques Jane Mills 8th United European Gastroenterology Week (UEGW) 11/25/2000 Brussels; Belgium
Medical condition
Irritable Colon
Product
alosetron
Collaborators
Not applicable
Study date(s)
May 1998 to November 1999
Type
Not applicable
Phase
3
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-30-11
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website